The invention relates to a new use of a long-acting mutant human fibroblast growth factor. The said long-acting mutant human fibroblast growth factor is PEGylation Recombinant Human-mouse Chimeric Fibroblast Growth Factor 21, and the said new use means the use in preparation of drugs for treating non-alcoholic steatohepatitis.